Synthetic Lethality Conference, Boston, 2017

Kongressthemen
Across 3 content-packed days, the field’s thought leaders from AstraZeneca, Tesaro, Artios, Metabomed, Sierra Oncology and many more will be sharing their insight and lessons learned, collectively enabling the community to:

- Achieve Efficacy across Contexts: Define the key steps required to identify and therapeutically exploit robust synthetic lethal interactions that are conserved across a variety of defined contexts.

Kongressorganizer (PCO)
Hanson Wade

Anmerkungen
Speakers: Graeme Smith - Chief Scientific Officer - Artios Pharma Ltd., J. Carl Barrett - Vice President of Translational science in Oncology - AstraZeneca and many more.

https://go.evvnt.com/160417-2

Frau Charlotte Harrison